» Articles » PMID: 17493790

Hyperthermia: a Potent Enhancer of Radiotherapy

Overview
Specialty Oncology
Date 2007 May 12
PMID 17493790
Citations 145
Authors
Affiliations
Soon will be listed here.
Abstract

Hyperthermia is generally regarded as an experimental treatment with no realistic future in clinical cancer therapy. This is totally wrong. Although the role of hyperthermia alone as a cancer treatment may be limited, there is extensive pre-clinical data showing that in combination with radiation it is one of the most effective radiation sensitisers known. Moreover, there are a number of large randomised clinical trials in a variety of tumour types that clearly show the potential of hyperthermia to significantly improve both local tumour control and survival after radiation therapy, without a significant increase in side-effects. Here we review the pre-clinical rationale for combining hyperthermia with radiation, and summarise the clinical data showing its efficacy.

Citing Articles

Synergistic effects of 6-shogaol and hyperthermia on ACHN renal cancer cells: modulation of ROS and heat shock pro-teins in cancer therapy.

Ahn C, Baek S Front Pharmacol. 2025; 16:1522285.

PMID: 40051570 PMC: 11882530. DOI: 10.3389/fphar.2025.1522285.


Modulated electro-hyperthermia therapy combined with Korean mistletoe extract treatment exerts a strong anti-tumor activity by enhancing cellular and humoral immune responses in mice.

Kim Y, Hur J, Hong S, Jung J, Park C, Park J Anim Cells Syst (Seoul). 2025; 29(1):163-172.

PMID: 40040867 PMC: 11878165. DOI: 10.1080/19768354.2025.2470455.


Delivering Volumetric Hyperthermia to Head and Neck Cancer Patient-Specific Models Using an Ultrasound Spherical Random Phased Array Transducer.

Zubair M, Uddin I, Dickinson R, Diederich C Bioengineering (Basel). 2025; 12(1).

PMID: 39851288 PMC: 11760898. DOI: 10.3390/bioengineering12010014.


Enhanced radiosensitivity of head and neck cancer cells to proton therapy via hyperthermia-induced homologous recombination deficiency.

Heemskerk T, van de Kamp G, Rovituso M, Kanaar R, Essers J Clin Transl Radiat Oncol. 2024; 51:100898.

PMID: 39720467 PMC: 11665703. DOI: 10.1016/j.ctro.2024.100898.


The Rationale for Combining Hypofractionated Radiation and Hyperthermia.

Sinha P, Folefac C, Overgaard J, Horsman M Cancers (Basel). 2024; 16(23).

PMID: 39682105 PMC: 11640455. DOI: 10.3390/cancers16233916.